270,000 Shares in Avanos Medical, Inc. $AVNS Acquired by Punch & Associates Investment Management Inc.

Punch & Associates Investment Management Inc. acquired a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 270,000 shares of the company’s stock, valued at approximately $3,032,000. Punch & Associates Investment Management Inc. owned 0.58% of Avanos Medical at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. ExodusPoint Capital Management LP grew its position in Avanos Medical by 61.0% in the 4th quarter. ExodusPoint Capital Management LP now owns 586,485 shares of the company’s stock worth $6,586,000 after purchasing an additional 222,292 shares in the last quarter. Magnetar Financial LLC grew its position in shares of Avanos Medical by 28.2% during the 4th quarter. Magnetar Financial LLC now owns 43,687 shares of the company’s stock valued at $491,000 after acquiring an additional 9,604 shares during the period. Barclays PLC grew its position in shares of Avanos Medical by 9.1% during the 4th quarter. Barclays PLC now owns 69,938 shares of the company’s stock valued at $785,000 after acquiring an additional 5,856 shares during the period. Marshall Wace LLP bought a new position in shares of Avanos Medical during the 4th quarter valued at approximately $765,000. Finally, Walleye Capital LLC bought a new position in shares of Avanos Medical during the 4th quarter valued at approximately $447,000. Institutional investors and hedge funds own 95.17% of the company’s stock.

Analyst Ratings Changes

AVNS has been the subject of several analyst reports. Weiss Ratings raised shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Friday, June 5th. Finally, Wall Street Zen downgraded shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Avanos Medical currently has a consensus rating of “Reduce”.

Avanos Medical Price Performance

Shares of NYSE:AVNS opened at $24.97 on Wednesday. The stock has a market cap of $1.17 billion, a PE ratio of -15.51 and a beta of 1.56. The company’s fifty day moving average is $23.49 and its 200 day moving average is $16.66. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $25.49. The company has a quick ratio of 1.40, a current ratio of 2.48 and a debt-to-equity ratio of 0.11.

Avanos Medical (NYSE:AVNS) last issued its earnings results on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. The company had revenue of $182.20 million for the quarter, compared to analysts’ expectations of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 EPS. Research analysts anticipate that Avanos Medical, Inc. will post 1.06 earnings per share for the current year.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.